Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

John A Mackintosh; Gregory Keir; Lauren K Troy; Anne E Holland; Christopher Grainge; Daniel C Chambers; Debra Sandford; Helen E Jo; Ian Glaspole; Margaret Wilsher; Nicole S L Goh; Paul N Reynolds; Sally Chapman; Steven E Mutsaers; Sally de Boer; Susanne Webster; Yuben Moodley; Tamera J Corte

doi:10.1111/resp.14656

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

Respirology. 2024 Feb;29(2):105-135. doi: 10.1111/resp.14656. Epub 2024 Jan 11.

Authors

John A Mackintosh^{1

2}, Gregory Keir³, Lauren K Troy^{4

5}, Anne E Holland^{2

6

7}, Christopher Grainge⁸, Daniel C Chambers^{1

2}, Debra Sandford^{2

9

10}, Helen E Jo^{4

5}, Ian Glaspole^{2

11}, Margaret Wilsher¹², Nicole S L Goh^{13

14

15}, Paul N Reynolds^{2

9

10}, Sally Chapman¹⁶, Steven E Mutsaers¹⁷, Sally de Boer¹², Susanne Webster⁴, Yuben Moodley^{2

16

17}, Tamera J Corte^{2

4

5}

Affiliations

¹ Department of Respiratory Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
² Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.
³ Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
⁴ Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
⁵ University of Sydney, Sydney, New South Wales, Australia.
⁶ Department of Physiotherapy, The Alfred Hospital, Melbourne, Victoria, Australia.
⁷ Department of Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
⁸ Department of Respiratory Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia.
⁹ Department of Thoracic Medicine, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
¹⁰ University of Adelaide, Adelaide, South Australia, Australia.
¹¹ Department of Respiratory Medicine, The Alfred Hospital, Melbourne, Victoria, Australia.
¹² Department of Respiratory Medicine, Te Toka Tumai Auckland, Auckland, New Zealand.
¹³ Department of Respiratory Medicine, Austin Hospital, Melbourne, Victoria, Australia.
¹⁴ Institute for Breathing and Sleep, Melbourne, Victoria, Australia.
¹⁵ University of Melbourne, Melbourne, Victoria, Australia.
¹⁶ Institute for Respiratory Health, University of Western Australia, Nedlands, Western Australia, Australia.
¹⁷ Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis.

Keywords: idiopathic pulmonary fibrosis; interstitial lung disease; progressive pulmonary fibrosis; pulmonary fibrosis; treatment.

MeSH terms

Australia
Fibrosis
Humans
Idiopathic Pulmonary Fibrosis* / drug therapy
New Zealand
Pyridones / therapeutic use

Substances

Pyridones

Abstract

MeSH terms

Substances

Grants and funding